ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,459.10
1.11%
US Tech 100
18,514.00
1.00%
Dow Jones
40,589.34
1.64%
Brent Oil
79.745
0.00%
Bitcoin
67,929.03
0.02%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Tevogen Bio Holdings Inc (TVGN) Quote

Tevogen Bio Holdings Inc

Tevogen Bio Holdings Inc (TVGN)

NASDAQ
0.68
-0.01
(-1.45%)
Closed July 27 4:00PM
Delayed by 15 minutes
0.72
0.04
(5.88%)
After Hours: 7:17PM
Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Premium

Key stats and details

Current Price
0.72
Bid
0.69
Ask
0.72
Volume
114,935
0.6683 Day's Range 0.6966
0.653 52 Week Range 21.09
Market Cap
119.602M
Previous Close
0.69
Open
0.6966
Last Trade
101
@
0.72
(formt)
Last Trade Time
Financial Volume
$ 78,672
VWAP
0.684487
Average Volume (3m)
689,848
Shares Outstanding
166,114,418
Dividend Yield
-
PE Ratio
-1,700.00
Earnings Per Share (EPS)
-0
Revenue
-
Net Profit
-67k

About Tevogen Bio Holdings Inc

Tevogen Bio is a leading NextGen clinical-stage specialty immunotherapy Biotech developing off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Tevogen Bio is a leading NextGen clinical-stage specialty immunotherapy Biotech developing off-the-shelf precision T cell therapeutics in virology, oncology, and neurology.

Sector
Biological Pds,ex Diagnstics
Industry
Blank Checks
Website
www.tevogen.com/
Headquarters
Wilmington, Delaware, USA
Founded
2024
Tevogen Bio Holdings Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker TVGN. The last closing price for Tevogen Bio was $0.69. Over the last year, Tevogen Bio shares have traded in a share price range of $ 0.653 to $ 21.09.

Tevogen Bio currently has 166,114,418 shares outstanding. The market capitalization of Tevogen Bio is $114.62 million. Tevogen Bio has a price to earnings ratio (PE ratio) of -1700.00.

TVGN Latest News

More News

Tevogen Bio Issues Letter to Stockholders Highlighting Recent Achievements, Growth Plans, and Consideration of a Potential Share Buyback

WARREN, N.J., July 11, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holding Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing...

July 11 2024
GlobeNewswire Inc.

Tevogen Bio’s R&D Leadership Discusses The Promise of Its Genetically Unmodified, Off-The-Shelf T Cell Technology For The Treatment of Infectious Diseases, Cancers, and Neurological Disorders With Nasdaq's Kristina Ayanian

Dr. Flomenberg and Dr. Grosso are leading experts in T cell biology and its clinical applicationsTevogen’s ExacTcell™ platform is designed to address current cost, and patient accessibility...

July 10 2024
GlobeNewswire Inc.

Ryan Saadi Congratulates Marc Benioff on Receiving the Yale Legend in Leadership Award and Commends Yale School of Management for Recognizing the Importance of Integrating Corporate Success with Social Responsibility

WARREN, N.J., July 08, 2024 (GLOBE NEWSWIRE) -- Ryan Saadi, MD, MPH, founding CEO of Tevogen Bio (“Tevogen”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing...

July 08 2024
GlobeNewswire Inc.

Tevogen Bio Files Registration Statement for Previously Disclosed Securities; Does Not Relate to Any Previously Undisclosed New Issuances of Dilutive Securities

This new registration statement does not relate to any previously undisclosed new issuances of dilutive securities.Includes issuance of shares underlying warrants originally issued in 2021...

June 26 2024
GlobeNewswire Inc.

Tevogen Bio Announces Publication of Positive Phase I Clinical Trial Results for TVGN 489 in Blood Advances

WARREN, N.J., June 25, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing...

June 25 2024
GlobeNewswire Inc.

Tevogen.AI Head Discusses Company’s Bold Strategy to Shape the Future of T Cell Therapies at Longwood Spring MIT Conference

WARREN, N.J., June 18, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing...

June 18 2024
GlobeNewswire Inc.

Tevogen Bio Set to Join Russell 3000® Index

WARREN, N.J., June 12, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing...

June 12 2024
GlobeNewswire Inc.

Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts

Includes $36 million line of credit and potential $14 million private placement WARREN, N.J., June 11, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq:...

June 11 2024
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.06175-7.898944675410.781750.820.66831293860.74929832CS
40.0233.299856527980.6970.840.6532151190.7233762CS
12-0.2366-24.73343090110.95661.480.6536898480.92533223CS
26-3.38-82.43902439024.121.090.6536695321.6932481CS
52-3.38-82.43902439024.121.090.6536695321.6932481CS
156-3.38-82.43902439024.121.090.6536695321.6932481CS
260-3.38-82.43902439024.121.090.6536695321.6932481CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
WINTWindtree Therapeutics Inc
$ 8.24
(150.46%)
48.57M
BFIBurgerFi International Inc
$ 0.4206
(97.37%)
313.59M
NBSTWNewbury Street Acquisition Corporation
$ 0.1349
(92.71%)
122.1k
YIBOPlanet Image International Ltd
$ 2.915
(53.43%)
260.07k
CREVCarbon Revolution Public Ltd
$ 9.00
(45.87%)
8.06M
NMHINatures Miracle Holding Inc
$ 0.2035
(-48.06%)
7.69M
TANHTantech Holdings Ltd
$ 0.2585
(-47.23%)
6.75M
DXCMDexCom Inc
$ 64.00
(-40.66%)
53.92M
PSIGPS International Group Ltd
$ 1.42
(-31.40%)
716.26k
POAIPredictive Oncology Inc
$ 1.36
(-27.27%)
6.02M
SLNASelina Hospitality PLC
$ 0.0305
(-18.88%)
408.61M
BFIBurgerFi International Inc
$ 0.4206
(97.37%)
313.59M
NVDANVIDIA Corporation
$ 113.06
(0.69%)
293.33M
SQQQProShares UltraPro Short QQQ
$ 9.10
(-2.88%)
176.49M
SGMOSangamo Therapeutics Inc
$ 0.8612
(28.15%)
123.71M

TVGN Discussion

View Posts
ChuckPaul63 ChuckPaul63 2 months ago
Corporate overview: Robust and IMPRESSIVE drug pipeline. (tevogen.com) $TVGN.
👍️ 1
harry crumb harry crumb 2 months ago
Pour souls on this scam
👍️0
glenn1919 glenn1919 2 months ago
TVGN.............................https://stockcharts.com/h-sc/ui?s=TVGN&p=W&b=5&g=0&id=p86431144783
👍️0
Invest-in-America Invest-in-America 2 months ago
TVGN: Up 52% in the Post-M right now behind last Friday's (Post-M) PR --- behind circa 15-mil. shares Float. Said (Post-Close) Friday news elaborated that they secured $51-mil. financing. Also, some recent April 2024 news about no more circa $91-mil. "liability" to worry about. (Whelp, not exactly a CURE for Cancer, so far, nor any of the many diseases they are targeting; but appears they are getting their MONEY in good order.)
https://www.globenewswire.com/news-release/2024/05/10/2879865/0/en/Tevogen-Bio-Announces-Up-to-50-Million-in-Financing-to-Further-Advance-Operational-Objectives.html (This identical PR was splattered over many, many, news media sites.)
👍️0
tw0122 tw0122 3 months ago
Jump jump
👍️0
Monksdream Monksdream 3 months ago
TVGN SPAC junk new 52 lo

👍️0
2020trader 2020trader 4 months ago
TVGN down 12% today, expecting lower
👍️0
Monksdream Monksdream 4 months ago
SPAC junk
👍️0
2020trader 2020trader 4 months ago
down 17% today
👍️0
2020trader 2020trader 4 months ago
expecting lower
👍️0
Monksdream Monksdream 4 months ago
Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?orderBy=percentChange&orderDir=desc
👍️0
Monksdream Monksdream 4 months ago
Will it grow legs after 9:30
https://ih.advfn.com/markets/nasdaq/premarket
👍️0
Monksdream Monksdream 4 months ago
Tevogen Bio Holdings Inc NASDAQ: TVGN

GoSymbol lookup
Health Care : Biotechnology | Company profile
Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company. The Company is harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs), to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the unmet needs of patient populations. Its first product candidate, TVGN 489, is an off-the-shelf, allogeneic cytotoxic CD8+ T cell therapy designed to fill a critical gap in COVID-19 therapeutic solutions for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of Long COVID. In addition to TVGN 489, it has several product candidates under early-stage development. The Company is developing Epstein-Barr virus (EBV) specific CTLs for potential use in multiple sclerosis (MS) and EBV-associated lymphomas. Its TVGN 601 is being developed for MS, and its TVGN 930 is being developed for EBV-associated lymphomas.
👍️0

Your Recent History

NASDAQ
TVGN
Tevogen Bio
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved